Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
暂无分享,去创建一个
Martin Pule | Adrian P Gee | Helen E Heslop | Cliona M Rooney | Enli Liu | Hao Liu | H. Heslop | C. Rooney | E. Yvon | A. Gee | M. Brenner | C. Rossig | H. Russell | B. Savoldo | G. Dotti | Gianpietro Dotti | Meng-fen Wu | Chrystal U Louis | Barbara Savoldo | Eric Yvon | G Doug Myers | Claudia Rossig | Heidi V Russell | Oumar Diouf | Hao Liu | Meng-Fen Wu | Zhuyong Mei | Malcolm K Brenner | C. Louis | Z. Mei | M. Pule | E. Liu | O. Diouf | G. D. Myers | Chrystal U. Louis | Helen E. Heslop | Barbara Savoldo | Gianpietro Dotti | Oumar Diouf | Meng Fen Wu | Cliona M. Rooney | Malcolm K. Brenner
[1] S. Riddell,et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. , 2011, Blood.
[2] J. Trapani,et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. , 2002, Blood.
[3] K. Matthay,et al. A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.
[4] P. Reuland,et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a , 2005, Cancer Immunology, Immunotherapy.
[5] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[6] S. Ferrone,et al. Mechanisms of immune evasion of human neuroblastoma. , 2005, Cancer letters.
[7] D. Srivastava,et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.
[8] F. Berthold,et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma , 2005, Cancer Immunology, Immunotherapy.
[9] M. Brenner,et al. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. , 2009, Current pharmaceutical design.
[10] C. Rooney,et al. Target Antigen Expression on a Professional Antigen-Presenting Cell Induces Superior Proliferative Antitumor T-Cell Responses via Chimeric T-Cell Receptors , 2006, Journal of immunotherapy.
[11] R. Gilbertson,et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. , 2007, Cancer research.
[12] J. Murray,et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Heslop,et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[15] N. Berger,et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Schrappe,et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. , 1995, European journal of cancer.
[17] S. Ferrone,et al. Immunogenicity of Human Neuroblastoma , 2004, Annals of the New York Academy of Sciences.
[18] D. Neuberg,et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell , 2007, Clinical Cancer Research.
[19] Mike Gough,et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.
[20] F. Berthold,et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Matthay,et al. A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group , 2006, Clinical Cancer Research.
[22] Sylvain Julien,et al. Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1 , 2008, The Journal of Immunology.
[23] H. Heslop,et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.
[24] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[25] J Pritchard,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[27] B. Kushner,et al. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Rooney,et al. Improving T cell therapy for cancer. , 2007, Expert opinion on biological therapy.
[29] A. Temme,et al. Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer , 2010, Journal of biomedicine & biotechnology.
[30] Egbert Oosterwijk,et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.
[31] K. Matthay,et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Sorkin,et al. Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia , 2010, PAIN®.
[33] Michel Sadelain,et al. The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.
[34] F. Berthold,et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy , 2011, BMC Cancer.
[35] H. Heslop,et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] C. Rooney,et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.
[37] Michel Sadelain,et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.
[38] Hao Liu,et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.
[39] S. Rosenberg,et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.